Immunotherapy for diffuse large B-cell lymphoma: Current landscape and future directions
Last Updated: Wednesday, December 15, 2021
This review article highlights the latest updates of immunotherapeutic agents in the management of DLBCL, including CD20-directed monoclonal antibody therapy, allogeneic and autologous stem cell transplant, CAR T-cell therapy, and immune checkpoint inhibitor therapy, among other therapeutic advances.
Advertisement
News & Literature Highlights